$CDXC News Article - A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen , Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) https://marketwirenews.com/news-releases/a-mi...91881.html